In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Alvotech

Generics Industry At The Forefront In War Against COVID-19 In 2021

As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.

Biosimilars Coronavirus COVID-19

Alvotech Eyes Canada Humira Launch As Celltrion Also Bags High-Strength Approval

The first biosimilar approval stemming from Alvotech’s collaboration with JAMP Pharma in Canada has arrived, with the firms’ Simlandi (adalimumab) biosimilar version of AbbVie’s higher-strength Humira. Celltrion has also announced an approval from Health Canada.

Approvals Strategy

Alvotech Welcomes EU Endorsement Of Higher-Strength Adalimumab

Alvotech has highlighted the significance to its global development strategy of the EU’s recent approval of its AVT02 higher-strength adalimumab biosimilar. However, one month on from approval, European marketing partner Stada has yet to confirm launch plans.

Biosimilars Approvals

Alvotech Differentiation Plans Include Interchangeable Golimumab

A proposal to merge with a special purpose acquisition company, in a move that will deliver longstanding plans for a public listing, has led biosimilars specialist Alvotech to discuss its ambitions and goals for its pipeline of seven biosimilar candidates.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Alvotech Iceland
    • Alvotech Germany GmnH
    • Alvotech Swiss AG
    • Glycothera
UsernamePublicRestriction

Register